No significant difference was found between other treatments .
Conclusion Compared with antimuscarinic drugs , PTENS was associated with significant better efficacy considering MVV , but more constipation events in de novo OAB children .
Antimuscarinic drugs showed remarkably better efficacy considering MVV and comparable safety profile compared with urotherapy .
Objective To compare these managements focusing on the efficacy and safety to treat overactive bladder ( OAB ) in children through network meta- analysis ( NMA ) .
Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
BACKGROUND Until now no confirmatory clinical trial in children suffering from nonneurogenic overactive bladder ( OAB ) and urinary incontinence could demonstrate superiority for antimuscarinics over placebo . OBJECTIVES The following study was conducted to prove efficacy and tolerability of propiverine compared to placebo . DESIGN , SETTING , AND PARTICIPANTS A r and omized , double-blind , placebo-controlled phase 3 trial with parallel-group design in children aged 5 - 10 yr was performed . Prior to the 8-wk medical therapy urologic baseline diagnostics , a 3-wk lifestyle advice ( urotherapy ) was established . INTERVENTION After re-evaluation of in- and exclusion criteria and uroflowmetry , only children fulfilling the requested criteria were allocated to a body-weight-adjusted therapy ( 10 or 15 mg propiverine twice daily or corresponding placebo ) . MEASUREMENTS Efficacy parameters derived from bladder diary and a micturition volume protocol . Decrease in voiding frequency per day was chosen as primary efficacy parameter ; secondary endpoints included voided volume and incontinence episodes . A safety assessment was conducted . RESULTS AND LIMITATIONS Of 171 r and omized children , 87 were treated with propiverine and 84 with placebo .  The primary efficacy parameter showed a decrease in voiding frequency ( -2.0 episodes for propiverine versus -1.2 for placebo ; p=0.0007 ) . Superiority could also be demonstrated for voided volume ( 31.4 vs. 5.1 ml ; p<0.0001 ) and incontinence episodes ( -0.5 vs. -0.2 episodes per d ; p=0.0005 ) . The trial design did not allow for separate evaluation of the effect of urotherapy prior to medical treatment . Propiverine was well-tolerated in children . Altogether 23 % of side-effects were reported for propiverine and 20 % for placebo . CONCLUSIONS This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence . An important additional factor for the success of the trial was a modified trial design with previous urotherapy . TRIAL REGISTRATION Clinical Trials.gov Identifier : NCT00603343
No significant difference was found between other treatments .
Conclusion Compared with antimuscarinic drugs , PTENS was associated with significant better efficacy considering MVV , but more constipation events in de novo OAB children .
Antimuscarinic drugs showed remarkably better efficacy considering MVV and comparable safety profile compared with urotherapy .
Objective To compare these managements focusing on the efficacy and safety to treat overactive bladder ( OAB ) in children through network meta- analysis ( NMA ) .